AI-Quantified ¹¹C-MET PET/CT bone marrow metabolic activity for prognostic assessment in newly diagnosed multiple myeloma
European Journal of Nuclear Medicine and Molecular Imaging · 2026-03 · 53 (4) · 2604-2621
DOI: 10.1007/s00259-025-07594-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 30.10.2025. Verfasst von Zanting Ye und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Biomedical Engineering, Southern Medical University, Guangzhou, 510515, China. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Bone Marrow, Methionine, Multiple Myeloma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: the National Natural Science Foundation of China, the National High-end Foreign Experts Recruitment Plan.
Abstract (Originalsprache)
PURPOSE: To develop and validate an AI method for automated quantification of whole-skeleton bone marrow (BM) metabolic activity using Carbon 11 (11C)-methionine (MET) PET/CT and to evaluate its prognostic value compared with Fluorine 18 (18F)-fluorodeoxyglucose (FDG) PET/CT in patients with newly diagnosed MM. METHODS: This prospective study included 49 patients (median age, 68 years; 29 males) with newly diagnosed MM. All patients underwent both 11C-MET and 18F-FDG PET/CT. An AI algorithm initially segments the skeleton on CT images, then propagates the resulting mask to the standardized uptake value (SUV) PET images for automated PET/CT segmentation and quantitative volumetric assessment of BM metabolism. By applying a series of SUV thresholds, the algorithm calculates 11C-MET metabolic tumor volume (MTV) and total lesion methionine uptake (TLMU). Associations with clinical markers (bone marrow plasma cell [BMPC] percentage, serum β₂-microglobulin, International Staging System [ISS]/Revised ISS [R-ISS] stage) and progression-free survival (PFS) were assessed. RESULTS: AI-quantified 11C-MET MTV and TLMU showed significant correlations with BMPC percentage (MTV: r = 0.32, p = 0.02; TLMU: r = 0.31, p = 0.03), serum β₂-microglobulin (MTV: r = 0.29, p = 0.05; TLMU: r = 0.29, p = 0.05), ISS stage (MTV: r = 0.31, p = 0.03; TLMU: r = 0.32, p = 0.03), and R-ISS stage (MTV: r = 0.40, p = 0.02; TLMU: r = 0.37, p = 0.03). In multivariable Cox analysis, both ¹¹C-MET MTV (HR = 1.0023; [95% CI: 1.0004-1.0042]; p = 0.02) and TLMU (HR = 1.0003; [95% CI: 1.0001-1.0005]; p = 0.01) independently predicted PFS. For PFS prediction, 11C-MET MTV (Area Under the Receiver Operating Characteristic Curve [AUC] = 0.743; [95% CI: 0.563-0.903]; p < 0.01) and TLMU (AUC = 0.749; [95% CI: 0.576-0.904]; p < 0.01) outperformed ¹⁸F-FDG PET/CT total lesion glycolysis (TLG) (AUC = 0.713, p < 0.01) and MTV (AUC = 0.719, p < 0.01) using the proposed thresholds. CONCLUSION: AI-quantified 11C-MET MTV and TLMU act as objective biomarkers of disease burden, they independently predict MM prognosis more effectively than 18F-FDG parameters and may enhance risk stratification.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Biomedical Engineering, Southern Medical University, Guangzhou, 510515, China.
- Departments of Nuclear Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510120, China.
- Department of Hematology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510120, China.
- School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, 200030, China.
- School of Biomedical Engineering, Southern Medical University, Guangzhou, 510515, China. ljlubme@gmail.com.
- Guangdong Provincial Key Laboratory of Medical Image Processing, Southern Medical University, Guangzhou, 510515, China. ljlubme@gmail.com.
ORCID-Profile: Lijun Lu
Förderung
- the National Natural Science Foundation of China
- the National High-end Foreign Experts Recruitment Plan
Zitieren
APA
Ye, Z., Lv, J., Wu, X., Li, H., Niu, X., Han, X., Li, B., Gao, L., Yang, J., Ouyang, F., Lu, L., & Ran, P. (2026). AI-Quantified ¹¹C-MET PET/CT bone marrow metabolic activity for prognostic assessment in newly diagnosed multiple myeloma. European Journal of Nuclear Medicine and Molecular Imaging, 53(4), 2604-2621. https://doi.org/10.1007/s00259-025-07594-4
Vancouver
Ye Z, Lv J, Wu X, Li H, Niu X, Han X, et al. AI-Quantified ¹¹C-MET PET/CT bone marrow metabolic activity for prognostic assessment in newly diagnosed multiple myeloma. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(4):2604-2621. doi:10.1007/s00259-025-07594-4
BibTeX
@article{Ye2026,
author = {Ye, Zanting and Lv, Jieqin and Wu, Xuanbin and Li, Hui and Niu, Xiaolong and Han, Xu and Li, Baoyuan and Gao, Lu and Yang, Jiaqi and Ouyang, Fu and Lu, Lijun and Ran, Pengcheng},
title = {AI-Quantified ¹¹C-MET PET/CT bone marrow metabolic activity for prognostic assessment in newly diagnosed multiple myeloma},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
volume = {53},
number = {4},
pages = {2604--2621},
doi = {10.1007/s00259-025-07594-4}
}
EUVIMED